CureVac’s CVGBM Shows Promise in Glioblastoma Study

CureVac (CVAC) has released an update.

CureVac’s Phase 1 study of its CVGBM cancer vaccine for glioblastoma has shown encouraging preliminary results, with a 77% induction of targeted T-cell responses in patients, 84% of which were newly initiated by the vaccine. The study, presented at the ESMO 2024 Congress, also reported the vaccine was well-tolerated at doses up to 100 µg, with manageable side effects, paving the way for future cancer vaccine developments utilizing CureVac’s mRNA technology.

For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.